

ADVENTRX PHARMACEUTICALS INC

Form 8-K

August 02, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **July 26, 2005**

**ADVENTRX Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-32157**

(Commission File Number)

**84-1318182**

(IRS Employer Identification No.)

**6725 Mesa Ridge Road, Suite 100**

**San Diego, California 92121**

(Address of principal executive offices) (Zip Code)

**(858) 552-0866**

(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On August 1, 2005, the Company announced the closing of its recently announced private placement of unregistered securities; and on July 26, 2005 the Company announced certain data on Thiovir, a preclinical compound in development.

The press releases issued by the Company on August 1, 2005 and July 26, 2005 with respect to these matters are included with this report as exhibits.

Item 9.01. Financial Statements and Exhibits.

(c) The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

**By:** /s/ Carrie E. Carlander

**Name:** Carrie E. Carlander

**Title:** Chief Financial Officer, Vice  
President, Finance, and Treasurer

August 2, 2005

---

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release of the Company dated August 1, 2005.
99.2	Press Release of the Company dated July 26, 2005.